RAPT TherapeuticsRAPT
About: RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Employees: 68
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
277.57% more ownership
Funds ownership: 85.39% [Q3] → 362.96% (+277.57%) [Q4]
233% more capital invested
Capital invested by funds: $59.9M [Q3] → $199M (+$140M) [Q4]
150% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 5 (+3) [Q4]
55% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 20
39% more call options, than puts
Call options by funds: $507K | Put options by funds: $365K
9% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 32
3% less funds holding
Funds holding: 94 [Q3] → 91 (-3) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Raghuram Selvaraju 29% 1-year accuracy 95 / 331 met price target | 1,073%upside $10 | Buy Reiterated | 10 Mar 2025 |
Financial journalist opinion








